Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by joe9999on Feb 24, 2017 11:34am
319 Views
Post# 25889303

DRUG CLINICAL STUDY: PHASE 2 (published yesterday)

DRUG CLINICAL STUDY: PHASE 2 (published yesterday)
PHASE 2: In Phase 2 studies, researchers administer the drug to a group of PATIENTS WITH THE DISEASE or condition for which the drug is being developed. Typically involving LESS patients than phase 3, these studies AREN'T LARGE ENOUGH to show whether the drug will be beneficial. Sometimes phase II clinical trials will assign different people to several possible treatments. This may include standard treatment compared with standard treatment plus the treatment being studied. Phase II clinical trials give doctors more information about the treatments safety and how well it works. Instead, Phase 2 studies provide researchers with ADDITIONNAL SAFETY DATA. Researchers use these data to refine research questions, develop research methods, and design new Phase 3 research protocols. Doctors need to show that the new treatment is likely to work and that its as safe as standard treatment. If it is, research can move to phase III clinical trials.
Bullboard Posts